T2 Biosystems, Inc.: Nasdaq/NYSE listing notice — T2 Biosystems receives Nasdaq delisting notice for market value below $35M

T2 Biosystems, Inc.

MVLS below $35M minimum for 30 consecutive business days as of Nov 22, 2022; compliance period ended May 22, 2023.
Nasdaq notified T2 on May 23, 2023 that shares fail to comply and are subject to delisting.
Company will appeal and request a hearing to stay delisting pending Panel decision.
T2 intends to present a plan to regain compliance, but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

T2 Biosystems, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

May 23, 2023 we received a letter from Nasdaq informing us that our shares have failed to comply with the MVLS required for continued listing on The Nasdaq Capital Market and, as a result, our shares are subject to delisting. We will file an appeal and hearing request with Nasdaq, which will stay the delisting of our common stock from The Nasdaq Capital Market pending a Nasdaq listing qualifications hearings panel’s (the “Panel”) decision. There can be no assurance that the Panel will grant our request for continued listing; however, we intend to present a plan to regain compliance to the Pane

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-151808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.